Travel pass: Pros may outweigh cons
IATA’s mobile application will allow travellers to store and manage certifications for Covid-19 tests or ...
A new study has revealed that 10 days after receiving the second dose of an mRNA Covid-19 vaccine, asymptomatic patients are far less likely to test positive, compared to patients who have not been vaccinated for the coronavirus.
With two doses of a messenger RNA Covid-19 vaccine, people with no symptoms showed an 80 per cent lower adjusted risk of testing positive for the coronavirus.
Also read: Surgeries should be postponed for Covid-19 patients; high death risk: Study
The study, published in the journal Clinical Infectious Diseases, has been carried out by researchers at Mayo Clinic.
The authors stated that these findings underscore the efficacy of messenger RNA vaccines for Covid-19 to significantly limit the spread of the virus by asymptomatic people, who may unknowingly spread the infection to others.
The researchers carried out a retrospective study of 39,000 patients who underwent pre-procedural molecular screening tests for Covid-19.
More than 48,000 screening tests were performed, including 3,000 on patients who had received at least one dose of a messenger RNA Covid-19 vaccine.
These screening tests were part of the routine Covid-19 testing prior to treatments not related to the infection, such as surgeries and other procedures.
Patients in the vaccinated group had received at least one dose of a messenger RNA Covid-19 vaccine.
Also read: Delaying Covid vaccine second dose can reduce case numbers in near term, says study
The researchers found that asymptomatic patients receiving at least one dose of the mRNA Covid-19 vaccine, 10 days or more prior to screening, were 72 per cent less likely to test positive, while those receiving two doses were 73 per cent less likely, compared to the non-vaccinated group.
After adjusting for a range of factors, researchers found an 80 per cent risk reduction of testing positive for Covid-19 among those with two doses of a messenger RNA Covid-19 vaccine.
IATA’s mobile application will allow travellers to store and manage certifications for Covid-19 tests or ...
A 2010 Act to regulate the medical sector flounders in implementation, even as healthcare remains ...
The scheme to boost local medtech manufacturing is timely, especially given the raging pandemic. But ...
Do pilots sleep on their job?
Fiscal stimulus, friendly monetary policy and firm commodity prices point towards normalcy, says the MD and ...
Price correction is a good opportunity for long-term investors to take the plunge
Q4 earnings, along with progress in controlling Covid-19 spread, will be in focus
Do keep in mind that premium may go up in case one of the members has a pre-existing condition
The hemming in of Mamata Banerjee by the BJP in what was once a Trinamool stronghold sums up the story of West ...
Inside Narayan Chandra Sinha’s universe house, metal and nature’s footprints are churned into an organic whole
A former resident relives sepia-tinted memories of growing up in a hilly, colonial tea range of the Western ...
It starts with the lack of new email messages: A sudden silence from my personal world. It’s a mellow Saturday ...
Monotype’s 2021 type trends report points to a return to hand and the familiar
As ‘ear-points’ between a company and a customer grow, we are witnessing a rise in audio assets
‘Desi Twitter challenger’ Koo on connecting like-minded folks
Coca-Cola has just introduced an oat milk line in the US under its Simply brand. Smart move, say industry ...
Three years after its inception, compliance with GST procedures remains a headache for exporters, job workers ...
Corporate social responsibility (CSR) initiatives of companies are altering the prospects for wooden toys of ...
Aequs Aerospace to create space for large-scale manufacture of toys at Koppal
And it has every reason to smile. Covid-19 has triggered a consumer shift towards branded products as ...
Please Email the Editor